MedPath

Novartis AG

Novartis AG logo
🇨🇭Switzerland
Ownership
Public, Private
Established
1996-01-01
Employees
76K
Market Cap
$242.6B
Website
https://www.novartis.com/our-science/novartis-institutes-biomedical-research
Introduction

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch

Phase 3
Completed
Conditions
Allergic Rhinoconjunctivitis
Interventions
Drug: Depiquick Birch (DPG103)
Drug: Placebo
First Posted Date
2013-07-19
Last Posted Date
2017-03-22
Lead Sponsor
Novartis
Target Recruit Count
202
Registration Number
NCT01902992
Locations
🇩🇪

Novartis Investigative Site, Witten, Germany

Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above

Phase 4
Completed
Conditions
Influenza
Interventions
Biological: Fluvirin(TIVf)
Biological: Agriflu (TIV)
First Posted Date
2013-06-03
Last Posted Date
2014-10-01
Lead Sponsor
Novartis
Target Recruit Count
2902
Registration Number
NCT01867021
Locations
🇿🇦

Site 33 - TREAD Research , Room 41, 8th Floor, Department of Cardiology, Tygerberg Hospital, Francie van Zijl Drive, Province of the Western Cape, Cape Town, South Africa

🇿🇦

Site 34 - Synopsis Research, Room 8, First floor, Fountain Centre, Belmont Road, Rondebosch, Cape Town, South Africa

🇿🇦

Site 43 - Allergy Diagnostic & Clinical Research Unit, UCT Lung Institute, George Street, Province of the Western Cape, Cape Town, South Africa

and more 22 locations

Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China

Completed
Conditions
Kidney Transplantation
First Posted Date
2013-02-22
Last Posted Date
2014-06-18
Lead Sponsor
Novartis
Target Recruit Count
1500
Registration Number
NCT01796639
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

🇨🇳

Nanfang Hospital, Guangzhou, Guangdong, China

🇨🇳

The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 15 locations

Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies

Completed
Conditions
Hepatitis C
Interventions
First Posted Date
2012-10-29
Last Posted Date
2016-04-08
Lead Sponsor
Novartis
Target Recruit Count
22
Registration Number
NCT01715779

Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain

Phase 4
Completed
Conditions
Ankle Sprain
Interventions
First Posted Date
2012-08-16
Last Posted Date
2014-04-17
Lead Sponsor
Novartis
Target Recruit Count
100
Registration Number
NCT01666197
Locations
🇩🇪

Investigator, Köln, Germany

Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI

Phase 3
Completed
Conditions
Upper Respiratory Infections
Interventions
First Posted Date
2012-04-27
Last Posted Date
2013-08-07
Lead Sponsor
Novartis
Target Recruit Count
56
Registration Number
NCT01586962
Locations
🇨🇦

Algorithme Pharma, Montreal, Quebec, Canada

Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)

Phase 3
Completed
Conditions
Upper Respiratory Infections
Interventions
Drug: IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
First Posted Date
2012-04-12
Last Posted Date
2013-11-11
Lead Sponsor
Novartis
Target Recruit Count
51
Registration Number
NCT01576809
Locations
🇨🇦

Algorithme Pharma, Montreal, Quebec, Canada

Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

Phase 1
Completed
Conditions
End Stage Renal Disease
Interventions
First Posted Date
2012-04-02
Last Posted Date
2012-04-02
Lead Sponsor
Novartis
Target Recruit Count
12
Registration Number
NCT01568775
Locations
🇩🇪

Charité Universitätsmedizin, Berlin, Germany

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India

Phase 3
Completed
Conditions
Bacterial Meningitis
Interventions
Biological: Meningococcal ACWY conjugate vaccine
First Posted Date
2012-03-08
Last Posted Date
2018-10-09
Lead Sponsor
Novartis
Target Recruit Count
180
Registration Number
NCT01547715
Locations
🇮🇳

Osmania Medical College Ethics Commitee, Niloufer Hospital, Hyderabad, Andrapradesh, India

🇮🇳

Padmasree Dr. D.Y Patil medical College, Pune, Maharashtra, India

🇮🇳

Bharati Vidyapeeth University Institutional Ethics Commitee, Katraj, Dhankawadi, India

and more 1 locations

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Phase 3
Completed
Conditions
Meningococcal Meningitis
Typhoid
Japanese Encephalitis
Meningococcal Disease
Yellow Fever
Rabies
Interventions
Biological: Rabies Vaccine
Biological: Typhoid Vi Polysaccharide Vaccine
Biological: Japanese Encephalitis Vaccine
Biological: Yellow Fever Vaccine
Biological: MenACWY-CRM Vaccine
First Posted Date
2011-11-08
Last Posted Date
2014-03-11
Lead Sponsor
Novartis
Target Recruit Count
552
Registration Number
NCT01466387
Locations
🇨🇿

Centrum ockovani a cestovni mediciny (Vaccination and Travel Medicine Centre) Poliklinika II, Bratri Stefanu 895, Hradec Kralove, Czech Republic

🇩🇪

University of Munich Georgenstr.5, Muenchen, Germany

🇩🇪

Berliner Centrum Fur Reise und Tropenmedizin, Jaegerstrasse 67-69, Berlin, Germany

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath